News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biopharma researchers will be able to use a new technology to explore biomarkers and pathways with more sensitivity and precision to create new diagnostics and improved oncology, neurology, cardiology and other therapies.
Recent regulatory approvals have led to biosimilars being perceived as a lower regulatory risk and more commercially viable, according to Coherus.
Horizon Discovery has licensed a zinc finger nuclease (ZFN) technology from Sigma-Aldrich and says the combination with its own platform will be “a big step forward in gene editing.”
Cell Signaling Technology launched a new HER3 rabbit monoclonal antibody (mAb) for researchers studying HER2-mediated breast, lung and ovarian tumors.